Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Prepaid Assets (2018 - 2026)

10x Genomics' Prepaid Assets history spans 8 years, with the latest figure at $22.2 million for Q4 2025.

  • On a quarterly basis, Prepaid Assets rose 14.42% to $22.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $22.2 million, a 14.42% increase, with the full-year FY2025 number at $22.2 million, up 14.42% from a year prior.
  • Prepaid Assets hit $22.2 million in Q4 2025 for 10x Genomics, up from $19.2 million in the prior quarter.
  • Over the last five years, Prepaid Assets for TXG hit a ceiling of $25.6 million in Q1 2025 and a floor of $13.3 million in Q2 2021.
  • Historically, Prepaid Assets has averaged $18.4 million across 5 years, with a median of $19.0 million in 2022.
  • Biggest five-year swings in Prepaid Assets: skyrocketed 103.52% in 2021 and later fell 10.0% in 2024.
  • Tracing TXG's Prepaid Assets over 5 years: stood at $13.9 million in 2021, then grew by 19.3% to $16.6 million in 2022, then grew by 13.34% to $18.8 million in 2023, then grew by 3.31% to $19.4 million in 2024, then rose by 14.42% to $22.2 million in 2025.
  • Business Quant data shows Prepaid Assets for TXG at $22.2 million in Q4 2025, $19.2 million in Q3 2025, and $20.4 million in Q2 2025.